Every SEC Form 3/4/5 on record for this filer (CIK 1589597) — 5 issuers, 104 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| PBYI | PUMA BIOTECHNOLOGY, INC. | Director | 2015-09-10 → 2026-06-15 | 18 | −$913,604 |
| KURA | Kura Oncology, Inc. | President and CEO · Director | 2016-02-02 → 2026-03-25 | 33 | −$18M |
| RNA | Atrium Therapeutics, Inc. | Director | 2020-06-11 → 2026-03-02 | 13 | −$6M |
| RNAM | Avidity Biosciences, Inc. | Director | 2026-02-27 → 2026-02-27 | 1 | — |
| ZSAN | Zosano Pharma Corp | Director · lapsed | 2016-11-04 → 2019-07-18 | 4 | — |
| Ticker | Date | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| PBYI | 2026-06-12 | Sell | 10,800 | $7.20 | $77,760 | 59,750 |
| KURA | 2025-09-29 | Sell | 36,615 | $8.94 | $327,338 | 246,853 |
| KURA | 2025-09-08 | Buy | 50,000 | $8.20 | $410,000 | 100,968 |
| RNA | 2025-09-05 | Sell | 14,500 | $50.00 | $725,000 | 69,425 |
3 of 5 issuers are covered and open a security page; the rest are on file here only.
